---
schema_version: "secwatch.filing_event.v1"
accession: "0001285550-24-000016"
form_type: "8-K"
ticker: "CLPT"
cik: "0001285550"
company_name: "ClearPoint Neuro, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:02:28.318310+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# ClearPoint Neuro reports Q4 2023 preliminary revenue $6.8M (+32% YoY); guides FY2024 revenue $28-32M

## Summary
- Preliminary Q4 revenue $6.8M, up 32% YoY; biologics/drug delivery revenue $4.1M (+76% YoY).
- Full year 2023 record revenue ~$24M (+17% YoY); biologics/drug delivery $13.6M (+49% YoY).
- Cash burn ~$1.2M in Q4; cash and equivalents $23.1M at Dec 31, 2023.
- FY2024 revenue guidance $28-32M (17-33% growth); expects multiple product launches including SmartFrame OR and PRISM laser.
- Company plans to expand to 100 ClearPoint sites by 2025 and demonstrate operating leverage.

## SEC filing metadata
- accession: 0001285550-24-000016
- form_type: 8-K
- ticker: CLPT
- cik: 0001285550
- company_name: ClearPoint Neuro, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000016/0001285550-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000016/clpt-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001285550-24-000016
- JSON: https://secwatch.observer/filing/0001285550-24-000016.json
- Plain text: https://secwatch.observer/filing/0001285550-24-000016.txt

## Key facts
- Earnings Releases
  ClearPoint Neuro, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue approximately $6.8 million.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: approximately $6.8 million
  - Result: preliminary results
  source text: a Form 10-K filing for the year with full financial statements. Fourth Quarter 2023 Preliminary Unaudited Financial Highlights • Preliminary unaudited revenue of approximately $6.8 million, a 32% year-over-year increase; • Increased biologics and drug delivery revenue to approximately $4.1 million, a 76% year-over-year increase; and • Cash burn of approximately
  evidence_url: https://www.sec.gov/Archives/edgar/data/1285550/000128555024000016/0001285550-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.